example-image3.jpg

Our pipeline

Dx
Diagnostic Radiopharmaceutical
Tx
Therapeutic Radiopharmaceutical
rh
Radiohybride
IE
Isotopic Exchange Reaction
OCD
On-Cartidge Drying of F-18
MS
Metabolically Stable or Stabilized Ligand
18F
Flourine-18
86Ga
Galium-68
177Lu
Lutetium-177
225Ac
Actinium-225

CANDIDATE SERIES

siPSMA

  • Indication Prostate Cancer and mCRPC
  • Application Imaging
  • Isotope F-18 prefferably
logo-scintomics.svg

Preclinical
Transition
Phase 1
Phase 2
Phase 3
Dx
Diagnostic Radiopharmaceutical
Tx
Therapeutic Radiopharmaceutical
rh
Radiohybride
IE
Isotopic Exchange Reaction
OCD
On-Cartidge Drying of F-18
MS
Metabolically Stable or Stabilized Ligand
18F
Flourine-18
86Ga
Galium-68
177Lu
Lutetium-177
225Ac
Actinium-225

CANDIDATE SERIES

sioPSMA

  • Indication Prostate Cancer and mCRPC
  • Application Therapy
  • Isotopes Lu-177, Ac-225
logo-scintomics.svg

Preclinical
Transition
Phase 1
Phase 2
Phase 3
Dx
Diagnostic Radiopharmaceutical
Tx
Therapeutic Radiopharmaceutical
rh
Radiohybride
IE
Isotopic Exchange Reaction
OCD
On-Cartidge Drying of F-18
MS
Metabolically Stable or Stabilized Ligand
18F
Flourine-18
86Ga
Galium-68
177Lu
Lutetium-177
225Ac
Actinium-225

CANDIDATE SERIES

rhTATE

  • Indication Neuroendocrine Tumors
  • Application Imaging
  • Isotope F-18 preffarably, Ga-68 alternatively
logo-scintomics.svg

Preclinical
Transition
Phase 1
Phase 2
Phase 3
Dx
Diagnostic Radiopharmaceutical
Tx
Therapeutic Radiopharmaceutical
rh
Radiohybride
IE
Isotopic Exchange Reaction
OCD
On-Cartidge Drying of F-18
MS
Metabolically Stable or Stabilized Ligand
18F
Flourine-18
86Ga
Galium-68
177Lu
Lutetium-177
225Ac
Actinium-225

CANDIDATE

chGRPR-1

  • Indication Prostate Cancer and mCRPC
  • Application Therapy
  • Isotope Lu-177
logo-scintomics.svg

Preclinical
Transition
Phase 1
Phase 2
Phase 3
Dx
Diagnostic Radiopharmaceutical
Tx
Therapeutic Radiopharmaceutical
rh
Radiohybride
IE
Isotopic Exchange Reaction
OCD
On-Cartidge Drying of F-18
MS
Metabolically Stable or Stabilized Ligand
18F
Flourine-18
86Ga
Galium-68
177Lu
Lutetium-177
225Ac
Actinium-225

CANDIDATES

chGRPR-2 / chGRPR-3

  • Indication Prostate Cancer and mCRPC
  • Application Imaging
  • Isotope Ga-68
logo-scintomics.svg

Preclinical
Transition
Phase 1
Phase 2
Phase 3
Dx
Diagnostic Radiopharmaceutical
Tx
Therapeutic Radiopharmaceutical
rh
Radiohybride
IE
Isotopic Exchange Reaction
OCD
On-Cartidge Drying of F-18
MS
Metabolically Stable or Stabilized Ligand
18F
Flourine-18
86Ga
Galium-68
177Lu
Lutetium-177
225Ac
Actinium-225

CANDIDATE SERIES

rhPSMA

  • Indication Prostate Cancer and mCRPC
  • Application Imaging
  • Isotope F-18
Blue-Earth 1.svg

Preclinical
Transition
Phase 1
Phase 2
Phase 3
Dx
Diagnostic Radiopharmaceutical
Tx
Therapeutic Radiopharmaceutical
rh
Radiohybride
IE
Isotopic Exchange Reaction
OCD
On-Cartidge Drying of F-18
MS
Metabolically Stable or Stabilized Ligand
18F
Flourine-18
86Ga
Galium-68
177Lu
Lutetium-177
225Ac
Actinium-225

CANDIDATE SERIES

rhPSMA

  • Indication Prostate Cancer and mCRPC
  • Application Therapy
  • Isotope Lu-177, Ac-225
Blue-Earth 1.svg

Preclinical
Transition
Phase 1
Phase 2
Phase 3
Dx
Diagnostic Radiopharmaceutical
Tx
Therapeutic Radiopharmaceutical
rh
Radiohybride
IE
Isotopic Exchange Reaction
OCD
On-Cartidge Drying of F-18
MS
Metabolically Stable or Stabilized Ligand
18F
Flourine-18
86Ga
Galium-68
177Lu
Lutetium-177
225Ac
Actinium-225

CANDIDATE SERIES

PSMA PNT 2001

  • Indication Prostate Cancer and mCRPC
  • Application Therapy
  • Isotope Lu-177, Ac-225
Point_logo.png

Preclinical
Transition
Phase 1
Phase 2
Phase 3
  • Address
  • SCINTOMICS GmbH
  • Jahnplatz 4
  • 82166 Gräfelfing
  • Germany
  • © 2023
website by Sensu